Novel blood pressure reducing composition

A composition and a technique for lowering blood pressure, applied in the field of medicine

Inactive Publication Date: 2011-11-23
FUKANGREN BIO PHARMA
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, they all have certain...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel blood pressure reducing composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: tablet

[0020] Name of raw material

1

2

3

4

5

Alikren Fumarate

150g

150g

150g

150g

150g

Levoclodipine Besylate

5g

7.5g

10g

----

----

Hydrochlorothiazide

----

25g

----

----

25g

Valsartan

----

----

40g

----

----

Captopril

----

----

----

25g

12.5g

microcrystalline cellulose

85g

80g

45g

65g

75g

lactose

36g

36g

36g

36g

36g

Sodium carboxymethyl cellulose

10g

10g

10g

10g

10g

pregelatinized starch

55g

55g

55g

55g

55g

Magnesium stearate

1.6g

1.6g

1.6g

1.6g

1.6g

purified water

Appropriate amount

Appropriate amount

Appropriate amount

Appropr...

Embodiment 2

[0023] Example 2: chewable tablet

[0024] Name of raw material

1

2

3

4

5

Alikren Fumarate

150g

150g

150g

150g

150g

Levoclodipine Besylate

5g

7.5g

10g

----

----

Hydrochlorothiazide

----

25g

----

----

25g

Valsartan

----

----

40g

----

----

Captopril

----

----

----

25g

12.5g

Mannitol

205g

195g

160g

185g

175g

Sorbitol

105g

105g

105g

105g

105g

Sodium carboxymethyl cellulose

10g

10g

10g

10g

10g

Sucralose

5g

5g

5g

5g

5g

essence

Appropriate amount

Appropriate amount

Appropriate amount

Appropriate amount

Appropriate amount

Magnesium stearate

1.6g

1.6g

1.6g

1.6g ...

Embodiment 3

[0027] Embodiment 3 curative effect verification experiment

[0028] The following is a curative effect evaluation experiment to further illustrate the curative effect advantages of the composition of the present invention.

[0029] 1. Experimental method:

[0030] Take 110 healthy male SD rats, and after one week of adaptive feeding, measure the basic blood pressure with RBP-1 rat blood pressure instrument. They fasted for 12 hours in the night before the operation, and made models the next morning. After 4 weeks of modeling, those whose blood pressure was more than 2.66kPa (3 standard deviations greater than normal blood pressure) and higher than 15.30kPa were determined to form a hypertensive disease model. The rats with successful modeling were randomly divided into: aliskiren (A), levamlodipine (B1), aliskiren + levamlodipine (B2); aliskiren + levamlodipine + hydrochlorothiazide (B3) , Olmesartan medoxomil (C1), Aliskiren + Olmesartan medoxomil (C2), Aliskiren + Olmesa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel blood pressure reducing composition. The blood pressure reducing composition is a medicinal composition of which active ingredients are any one or two of aliskiren and a medicinal salt thereof, a hydrate, a calcium channel blocker (CCB), an angiotensin type 1 (AT1) receptor blocker (ARB), an angiotensin-converting enzyme inhibitor (ACEI), hydrochlorothiazide and the like. The composition can be prepared into oral tablets or capsules and is used for treating hypertension, and the curative effect is superior to the blood pressure reducing effect of the independent aliskiren.

Description

technical field [0001] The invention is a novel blood pressure lowering composition, which belongs to the technical field of medicine. Background technique [0002] Hypertension is the most prevalent cardiovascular disease in the world today, and it is also an important risk factor for coronary heart disease, stroke and renal failure. Patients with hypertension not only have increased blood pressure and abnormal hemodynamics, but also often accompanied by It is a systemic disease with sugar and lipid metabolism disorders and damage to target organs such as the heart, brain, and kidneys. There are many antihypertensive drugs clinically, including diuretics, β-blockers, angiotensin converting enzyme inhibitors (ACE-I), angiotensin II (AT II) receptor antagonists, calcium antagonists and α - blockers. However, they all have certain limitations and side effects in use. Therefore, antihypertensive drugs with small side effects, good tolerance, and stable efficacy will be widel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/165A61K31/4422A61K31/41A61K31/4184A61K31/4178A61K31/401A61K31/403A61K31/675A61K31/55A61K31/216A61K31/549A61P9/12
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products